To establish whether this increase in ET-1 levels promoted the development of PAH, we treated fpnC326Yfl/fl SMMHC-CreERT2+ mice with the cyclic peptide BQ-123, a selective endothelin subtype-A receptor antagonist using slow release osmotic minipumps. This evidence concerns the gene EDN1 and pulmonary arterial hypertension.